CONTINUUM: Lifelong Learning in Neurology:
doi: 10.1212/01.CON.0000443828.41895.dc
Contributors

CONTRIBUTORS

Free Access
Article Outline
Collapse Box

Author Information

aRelationship Disclosure

bUnlabeled Use of Products/Investigational Use Disclosure

Died April 20, 2013

Autumn Klein, MD, PhD, Guest Editor†

Chief of the Division of Women’s Neurology, Assistant Professor of Neurology and Obstetrics and Gynecology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Amaal AlDakheel, MD

Clinical Fellow, The Morton and Gloria Shulman Movement Disorders Centre in the Edmond J. Safra Program for Parkinson’s Disease, Toronto Western Hospital, Krembil Neuroscience Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada

a,bDr AlDakheel reports no disclosures.

Riley M. Bove, MD

Instructor in Neurology, Harvard Medical School; Associate Neurologist, Brigham and Women’s Hospital, Boston, Massachusetts

a,bDr Bove reports no disclosures.

Patricia K. Coyle, MD, FAAN

Professor of Neurology and Vice Chair (Clinical Affairs); Director, Stony Brook MS Comprehensive Care Center, Stony Brook University, Stony Brook, New York

aDr Coyle has consulted for Acorda Therapeutics; Accordant Health Services; Bayer AG; Biogen Idec; Genentech, Inc; Genzyme Corporation; Merck KGaA; Mylan Inc; Novartis Corporation; and Teva Pharmaceuticals. Dr Coyle receives clinical trial support from Actelion Pharmaceuticals; Novartis Corporation; and Opexa Therapeutics, Inc.

bDr Coyle discusses the unlabeled use of IV immunoglobulin postpartum.

Carolina De Jesus-Acosta, MD

Fellow, Neuromuscular Medicine, Duke University Medical Center, Durham, North Carolina

aDr De Jesus-Acosta reports no disclosure.

bDr De Jesus-Acosta discusses the use of drugs for the treatment of myasthenia gravis, none of which are labeled by the US Food and Drug Administration for use in pregnancy.

Kathleen B. Digre, MD, FAAN

Professor, Departments of Neurology of Ophthalmology; Adjunct Professor, Department of Obstetrics and Gynecology, Moran Eye Center, University of Utah

aDr Digre has received a grant from the National Eye Institute and salary support from the Neuro-ophthalmology Research Disease Investigator Consortium.

bDr Digre discusses the use of several drugs for the treatment of neuro-ophthalmic disorders, none of which are labeled by the US Food and Drug Administration for use in pregnancy.

Steven K. Feske, MD

Associate Professor of Neurology, Harvard Medical School; Director, Stroke Division, Brigham and Women’s Hospital, Boston, Massachusetts

aDr Feske has received royalties from Elsevier for his role as editor of Office Practice of Neurology, 2nd Edition, and receives research support from the National Institute of Neurological Disorders and Stroke.

bDr Feske reports no disclosure.

Amanda C. Guidon, MD

Instructor of Neurology, Harvard Medical School; Assistant in Neurology, Massachusetts General Hospital, Boston, Massachusetts

a,bDr Guidon reports no disclosures.

Cynthia L. Harden, MD

Professor of Neurology; Chief, Division of Epilepsy and Electroencephalography, Hofstra North Shore–LIJ School of Medicine, Great Neck, New York

aDr Harden has received personal compensation for activities with GlaxoSmithKline; Lundbeck; UCB SA; and Upsher-Smith Laboratories, Inc. Dr Harden has served in an editorial capacity for UpToDate and received research support from the Epilepsy Therapy Project.

bDr Harden reports no disclosure.

Joseph S. Kass, MD, JD

Associate Professor of Neurology, Psychiatry, and Medical Ethics, Baylor College of Medicine, Houston, Texas

a,bDr Kass reports no disclosures.

Krista Kinard, MD

Instructor, Department of Ophthalmology, Moran Eye Center, University of Utah

aDr Kinard reports no disclosure.

bDr Kinard discusses the use of several drugs for the treatment of neuro-ophthalmic disorders, none of which are labeled by the US Food and Drug Administration for use in pregnancy.

Joshua P. Klein, MD, PhD

Chief, Division of Hospital Neurology, Brigham and Women’s Hospital; Assistant Professor of Neurology and Radiology, Harvard Medical School, Boston, Massachusetts

aDr Klein receives financial compensation for serving on the editorial board of the Journal of Neuroimaging and AccessMedicine Neurology, and royalties from McGraw-Hill for Adams and Victor’s Principles of Neurology.

bDr Klein reports no disclosure.

E. Anne MacGregor, MB BS, MD, FFSRH, MICR

Associate Specialist, Barts Sexual Health Centre, St Bartholomew’s Hospital; Honorary Professor, Centre for Neuroscience and Trauma, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, England, United Kingdom

aProfessor MacGregor has acted as a paid consultant to and/or her department has received research funding from Addex Therapeutics; Allergan, Inc; AstraZeneca; Berlin-Chemie AG; BTG International Ltd; Endo Pharmaceuticals Inc; GlaxoSmithKline; the Menarini Group; Merck & Co, Inc; POZEN Inc; and UniPath.

bProfessor MacGregor discusses the use of several drugs for the treatment of headaches, none of which are labeled by the US Food and Drug Administration for use in pregnancy.

E. Wayne Massey, MD, FAAN

Professor, Department of Neurology, Duke University Medical Center, Durham, North Carolina

a,bDr Massey reports no disclosures.

Janice M. Massey, MD, FAAN

Professor, Department of Neurology; Chief, Neuromuscular Division, Duke University Medical Center, Durham, North Carolina

aDr Massey has received educational grants from Allergan, Inc; and Merz Pharma.

bDr Massey discusses the use of drugs for the treatment of myasthenia gravis, none of which are labeled by the US Food and Drug Administration for use in pregnancy.

Janis M. Miyasaki, MD, MEd, FRCP, FAAN

Associate Professor, Department of Medicine, and Associate Clinical Director, The Movement Disorders Centre, Toronto Western Hospital, Krembil Neuroscience Centre, University Health Network, University of Toronto, Toronto, Ontario; Associate Professor, Neurology, University of Alberta, Edmonton, Alberta, Canada

aDr Miyasaki has served as a speaker or on advisory boards for Novartis Corporation and Teva Pharmaceuticals. Dr Miyasaki has received research support from the Canadian Agency for Drugs and Technologies in Health, the Canadian Institute for Health Research, the Michael J. Fox Foundation for Parkinson’s Research, the National Center for Complementary and Alternative Medicine, the National Parkinson Foundation, the NIH, the Ontario Drug Benefits Program, and the Ontario Ministry of Health and Long-Term Care. The Movement Disorders Centre at Toronto Western Hospital has received research support from Teva Pharmaceuticals.

bDr Miyasaki reports no disclosure.

Bethanie N. Morgan-Followell, MD

Assistant Professor of Pediatrics, Section of Child Neurology, Nationwide Children’s Hospital, The Ohio State University, Columbus, Ohio

aDr Morgan-Followell reports no disclosure.

bDr Morgan-Followell discusses the unlabeled use of disease-modifying therapies during attempts at conception and during pregnancy.

Jacqueline A. Nicholas, MD, MPH

Assistant Professor of Neurology, Division of Neuroimmunology, The Ohio State University Medical Center, Columbus, Ohio

aDr Nicholas’ fellowship is funded through a Sylvia Lawry Physician Fellowship grant from the National Multiple Sclerosis Society, and she receives additional funding for clinical research from the National Multiple Sclerosis Society as an assistant professor.

bDr Nicholas discusses the unlabeled use of disease-modifying therapies during attempts at conception and during pregnancy.

Laura B. Powers, MD, FAAN

Dr Powers is retired from private practice.

aDr Powers serves as ICD-9-CM Advisor for the Coding Subcommittee of the AAN Medical Economics and Management Committee and serves in an editorial capacity for Neurology: Clinical Practice.

bDr Powers reports no disclosure.

Aneesh B. Singhal, MD

Associate Professor of Neurology, Harvard Medical School; Director, Neurology Quality and Safety, Massachusetts General Hospital, Boston, Massachusetts

aDr Singhal has served as a consultant for Biogen Idec and as a medical expert witness in cases of stroke. Dr Singhal’s spouse holds stock or stock options greater than 5% of the company or greater than $10,000 in value in Biogen Idec and Vertex Pharmaceuticals Incorporated. Dr Singhal has received research support from the National Institute of Neurological Disorders and Stroke, and his institution has received research support from Pfizer Inc and PhotoThera, Inc, for clinical trial participation.

bDr Singhal reports no disclosure.

Pedro Weisleder, MD, PhD

Professor, Department of Pediatrics, Nationwide Children’s Hospital, The Ohio State University, Columbus, Ohio

aDr Weisleder serves as a consultant for the Medical Review Institute of America and as associate editor of the Journal of Child Neurology.

bDr Weisleder discusses the unlabeled use of disease-modifying therapies during attempts at conception and during pregnancy.

Mark S. Yerby, MD, MPH, FAAN

Founder, North Pacific Epilepsy Research; Chair, Scientific Advisory Board, North American Epilepsy and Pregnancy Registry; Associate Clinical Professor of Neurology and Public Health, Oregon Health & Science University, Portland, Oregon

aDr Yerby serves on the speakers bureaus for Lundbeck and Supernus Pharmaceuticals, Inc.

bDr Yerby reports no disclosure.

Back to Top | Article Outline

SELF-ASSESSMENT AND CME TEST WRITERS

Eduardo E. Benarroch, MD, DSci, FAAN

Professor of Neurology, Mayo Clinic, Rochester, Minnesota

aDr Benarroch has received personal compensation in an editorial capacity for Neurology.

bDr Benarroch reports no disclosure.

Ronnie Bergen, MD

Assistant Professor of Clinical Neurology, University of Arizona College of Medicine, Tucson, Arizona; Staff Neurologist, Southern Arizona VA Healthcare System, Tucson, Arizona

a,bDr Bergen reports no disclosures.

Copyright © 2014 by the American Academy of Neurology.

Login